Clinical Trials Logo

Clinical Trial Summary

A randomized crossover trial of ALAN intervention was conducted in patients with chronic schizophrenia in Anhui Mental Health Center from August 15 to September 30, 2022. All participants met the diagnostic criteria for schizophrenia in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V). The enrolled patients were in the symptom-stable phase and were regularly prescribed antipsychotics (no change in medication regimen). The diets of all the participants were uniformly supplied during study. Patients with infectious diseases, eye diseases, or gastrointestinal diseases, or who used antibiotics at the time of recruitment, were excluded. The wards of the participants were all located in the same inpatient building. All included wards had the same size, layout, lighting and orientation of doors and windows. In normal conditions, each ward retains a small LED lamp (the same layout in all wards) at night as a source of lighting. The study was divided into two stages. In the first stage, 10 wards were randomly selected as the intervention group (opaque black tape covering part of the light source), and another 10 wards were selected as the control group (no intervention). After a two-week washout interval, the second stage was carried out, with the two groups interchanging interventions. At the end of each intervention, participants completed a structured questionnaire scale to assess the relapse risk of schizophrenia, and then their fecal samples were collected.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05986409
Study type Interventional
Source Anhui Medical University
Contact
Status Completed
Phase N/A
Start date August 1, 2022
Completion date September 30, 2022

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03090490 - 10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals N/A
Completed NCT03558529 - Feasibility and Acceptability of a Smartphone App to Assess Early Warning Signs of Psychosis Relapse
Completed NCT02220504 - 3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals N/A
Recruiting NCT05473741 - Risk of Breakthrough Symptoms With Long-Acting Injectable Medications
Completed NCT03019887 - Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction N/A